Summary: <p>It’s been roughly six months since AstraZeneca released a COVID-19 antibody treatment called Evusheld, designed for immunocompromised people. But a lack of outreach and unequal distribution has led to a complicated and confusing rollout — leaving millions of vulnerable Americans without protection. Plus, what experts look for in the minutes from Federal Reserve meetings and how high energy prices please investors but burden the economy.</p>
